Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 1, 2015, Pages 17-27

  Hirsova, Petra ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Apoptosis; Caspase Inhibitor; Cell Death; Death Receptors; Exosomes; Extracellular Vesicles; Fibrosis; Inflammasome; Inflammation; Microvesicles; Necroptosis; Pyroptosis

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE INHIBITOR; CHEMOKINE RECEPTOR CCR2; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; INTERLEUKIN 1BETA; PUMA PROTEIN; RHO KINASE; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CELL ACTIVATION; CELL DEATH; CHROMATIN CONDENSATION; DNA FRAGMENTATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; KUPFFER CELL; LIPOAPOPTOSIS; LIPOTOXICITY; LIVER CELL; NATURAL KILLER T CELL; NECROPTOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PYROPTOSIS; REVIEW; UPREGULATION;

EID: 84928183267     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2014.11.005     Document Type: Review

References (87)

1. Fujii H., Kawada N. Inflammation and fibrogenesis in steatohepatitis. JGastroenterol 2012, 47:215-225.
2. Luedde T., Kaplowitz N., Schwabe R.F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014, 147:765-783.e4.
3. Amir M., Czaja M.J. Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011, 5:159-166.
4. Guicciardi M.E., Malhi H., Mott J.L., Gores G.J. Apoptosis and necrosis in the liver. Compr Physiol 2013, 3:977-1010.
5. Linkermann A., Green D.R. Necroptosis. N Engl J Med 2014, 370:455-465.
6. Chen X., Li W., Ren J., et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2014, 24:105-121.
7. Cai Z., Jitkaew S., Zhao J., et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nature Cell Biol 2014, 16:55-65.
8. Dillon C.P., Oberst A., Weinlich R., et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Reports 2012, 1:401-407.
9. Liedtke C., Bangen J.M., Freimuth J., et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 2011, 141:2176-2187.
10. Kaufmann T., Jost P.J., Pellegrini M., et al. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity 2009, 30:56-66.
11. Miao E.A., Rajan J.V., Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011, 243:206-214.
12. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13:333-342.
13. Shi J., Zhao Y., Wang Y., Gao W., et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014, 514:187-192.
14. Kubes P., Mehal W.Z. Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172.
15. Yamada K., Mizukoshi E., Sunagozaka H., et al. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int 2014, Published online. doi:10.1111/liv.12685.
16. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
17. Listenberger L.L., Han X., Lewis S.E., et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003, 100:3077-3082.
18. de Almeida I.T., Cortez-Pinto H., Fidalgo G., et al. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002, 21:219-223.
19. Han M.S., Park S.Y., Shinzawa K., et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. JLipid Res 2008, 49:84-97.
20. Kakisaka K., Cazanave S.C., Fingas C.D., et al. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2012, 302:G77-G84.
21. Alkhouri N., Carter-Kent C., Feldstein A.E. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 2011, 5:201-212.
22. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
23. Puri P., Mirshahi F., Cheung O., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134:568-576.
24. Cazanave S.C., Mott J.L., Bronk S.F., et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. JBiol Chem 2011, 286:39336-39348.
25. Lu M., Lawrence D.A., Marsters S., et al. Cell death. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 2014, 345:98-101.
26. Wei Y., Wang D., Topczewski F., Pagliassotti M.J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006, 291:E275-E281.
27. Cazanave S.C., Elmi N.A., Akazawa Y., et al. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2010, 299:G236-G243.
28. Barreyro F.J., Kobayashi S., Bronk S.F., et al. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. JBiol Chem 2007, 282:27141-27154.
29. Akazawa Y., Cazanave S., Mott J.L., et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. JHepatol 2010, 52:586-593.
30. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. JClin Invest 1999, 104:155-162.
31. Malhi H., Barreyro F.J., Isomoto H., et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007, 56:1124-1131.
32. Hirsova P., Ibrahim S.H., Bronk S.F., et al. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS One 2013, 8:e70599.
33. Volkmann X., Fischer U., Bahr M.J., et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007, 46:1498-1508.
34. Idrissova L, Malhi H, Werneburg NW, etal. Trail receptor deletion in mice suppresses the inflammation of nutrient excess. J Hepatol. Published online. doi:10.1016/j.jhep.2014.11.033.
35. Feldstein A.E., Canbay A., Guicciardi M.E., et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. JHepatol 2003, 39:978-983.
36. Siebler J., Schuchmann M., Strand S., et al. Enhanced sensitivity to CD95-induced apoptosis in ob/ob mice. Dig Dis Sci 2007, 52:2396-2402.
37. Zou C., Ma J., Wang X., et al. Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 2007, 13:1078-1085.
38. Crespo J., Cayon A., Fernandez-Gil P., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
39. Ribeiro P.S., Cortez-Pinto H., Sola S., et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004, 99:1708-1717.
40. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
41. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
42. Memon R.A., Grunfeld C., Feingold K.R. TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 2001, 7:2-3.
43. Sun X., Lee J., Navas T., et al. RIP3, a novel apoptosis-inducing kinase. JBiol Chem 1999, 274:16871-16875.
44. Csak T., Dolganiuc A., Kodys K., et al. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology 2011, 53:1917-1931.
45. Gautheron J., Vucur M., Reisinger F., et al. Apositive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014, 6:1062-1074.
46. Hatting M., Zhao G., Schumacher F., et al. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. Hepatology 2013, 57:2189-2201.
47. Barreyro F.J., Holod S., Finocchietto P.V., et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int 2014, Published online. doi:10.1111/liv.12570.
48. Witek R.P., Stone W.C., Karaca F.G., et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009, 50:1421-1430.
49. Dixon L.J., Flask C.A., Papouchado B.G., et al. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One 2013, 8:e56100.
50. Wree A., McGeough M.D., Pena C.A., et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. JMol Med (Berl) 2014, 92:1069-1082.
51. Wree A., Eguchi A., McGeough M.D., et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014, 59:898-910.
52. Silvestre-Roig C., de Winther M.P., Weber C., et al. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 2014, 114:214-226.
53. Chu W.M. Tumor necrosis factor. Cancer Lett 2013, 328:222-225.
54. Azijli K., Weyhenmeyer B., Peters G.J., et al. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ 2013, 20:858-868.
55. Azijli K., Yuvaraj S., Peppelenbosch M.P., et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. JCell Sci 2012, 125:4651-4661.
56. Collison A., Foster P.S., Mattes J. Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 2009, 36:1049-1053.
57. Cullen S.P., Henry C.M., Kearney C.J., et al. Fas/CD95-induced chemokines can serve as "find-me" signals for apoptotic cells. Mol Cell 2013, 49:1034-1048.
58. Marra F., Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014, 147:577-594.e1.
59. Andaloussi E.L., Mäger I., Breakefield X.O., Wood M.J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013, 12:347-357.
60. Canbay A., Feldstein A.E., Higuchi H., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003, 38:1188-1198.
61. Povero D., Eguchi A., Niesman I.R., et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal 2013, 6:ra88.
62. Bretz N.P., Ridinger J., Rupp A.K., et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. JBiol Chem 2013, 288:36691-36702.
63. Racanelli V., Rehermann B. The liver as an immunological organ. Hepatology 2006, 43(SUPPL):S54-S62.
64. De Vito R., Alisi A., Masotti A., et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med 2012, 30:49-56.
65. Miura K., Yang L., van Rooijen N., et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 2012, 302:G1310-G1321.
66. Tosello-Trampont A.C., Landes S.G., Nguyen V., et al. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. JBiol Chem 2012, 287:40161-40172.
67. Guebre-Xabier M., Yang S., Lin H.Z., et al. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000, 31:633-640.
68. Li Z., Soloski M.J., Diehl A.M. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005, 42:880-885.
69. Yang L., Jhaveri R., Huang J., et al. Endoplasmic reticulum stress, hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Lab Invest 2007, 87:927-937.
70. Syn W.K., Oo Y.H., Pereira T.A., et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010, 51:1998-2007.
71. Wolf M.J., Adili A., Piotrowitz K., et al. Metabolic activation of intrahepatic CD8(+) T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 2014, 26:549-564.
72. Kumar V. NKT-cell subsets: promoters and protectors in inflammatory liver disease. JHepatol 2013, 59:618-620.
73. Henning J.R., Graffeo C.S., Rehman A., et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 2013, 58:589-602.
74. Tacke F., Yoneyama H. From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. Hepatology 2013, 58:494-496.
75. Argo C.K., Northup P.G., Al-Osaimi A.M., Caldwell S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. JHepatol 2009, 51:371-379.
76. Canbay A., Friedman S., Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
77. Canbay A., Taimr P., Torok N., et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003, 83:655-663.
78. Povero D., Eguchi A., Feldstein A.E. Hepatocytes-derived microparticles released during lipotoxicity induce hepatic stellate cells activation and migration. Hepatology 2013, 58(SUPPL):S574A-S575A.
79. Thapaliya S., Wree A., Povero D., et al. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig Dis Sci 2014, 59:1197-1206.
80. Canbay A., Feldstein A., Baskin-Bey E., et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. JPharmacol Exp Ther 2004, 308:1191-1196.
81. Anstee Q.M., Concas D., Kudo H., et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. JHepatol 2010, 53:542-550.
82. Ratziu V., Sheikh M.Y., Sanyal A.J., et al. Aphase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012, 55:419-428.
83. Csak T., Ganz M., Pespisa J., et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
84. Dixon L.J., Berk M., Thapaliya S., et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest 2012, 92:713-723.
85. Kamari Y., Shaish A., Vax E., et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. JHepatol 2011, 55:1086-1094.
86. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139:323-334.e7.
87. Braddock M., Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004, 3:330-339.